Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
J Cardiovasc Magn Reson ; 19(1): 23, 2017 Jan 20.
Article in English | MEDLINE | ID: mdl-28187739

ABSTRACT

BACKGROUND: With multifaceted imaging capabilities, cardiovascular magnetic resonance (CMR) is playing a progressively increasing role in the management of various cardiac conditions. A global registry that harmonizes data from international centers, with participation policies that aim to be open and inclusive of all CMR programs, can support future evidence-based growth in CMR. METHODS: The Global CMR Registry (GCMR) was established in 2013 under the auspices of the Society for Cardiovascular Magnetic Resonance (SCMR). The GCMR team has developed a web-based data infrastructure, data use policy and participation agreement, data-harmonizing methods, and site-training tools based on results from an international survey of CMR programs. RESULTS: At present, 17 CMR programs have established a legal agreement to participate in GCMR, amongst them 10 have contributed CMR data, totaling 62,456 studies. There is currently a predominance of CMR centers with more than 10 years of experience (65%), and the majority are located in the United States (63%). The most common clinical indications for CMR have included assessment of cardiomyopathy (21%), myocardial viability (16%), stress CMR perfusion for chest pain syndromes (16%), and evaluation of etiology of arrhythmias or planning of electrophysiological studies (15%) with assessment of cardiomyopathy representing the most rapidly growing indication in the past decade. Most CMR studies involved the use of gadolinium-based contrast media (95%). CONCLUSIONS: We present the goals, mission and vision, infrastructure, preliminary results, and challenges of the GCMR. TRIAL REGISTRATION: Identification number on ClinicalTrials.gov: NCT02806193 . Registered 17 June 2016.


Subject(s)
Cardiovascular Diseases/diagnostic imaging , Magnetic Resonance Imaging , Registries , Research Design , Societies, Scientific , Cardiovascular Diseases/pathology , Cardiovascular Diseases/physiopathology , Cardiovascular Diseases/therapy , Contrast Media/administration & dosage , Cooperative Behavior , Humans , International Cooperation , Internet/organization & administration , Organizational Objectives , Predictive Value of Tests , Prognosis
3.
J Am Heart Assoc ; 4(12)2015 Dec 18.
Article in English | MEDLINE | ID: mdl-26683218

ABSTRACT

BACKGROUND: Myocardial fibrosis (MF) in noninfarcted myocardium may be an interstitial disease pathway that confers vulnerability to hospitalization for heart failure, death, or both across the spectrum of heart failure and ejection fraction. Hospitalization for heart failure is an epidemic that is difficult to predict and prevent and requires potential therapeutic targets associated with outcomes. METHOD AND RESULTS: We quantified MF with cardiovascular magnetic resonance extracellular volume fraction (ECV) measures in 1172 consecutive patients without amyloidosis or hypertrophic or stress cardiomyopathy and assessed associations with outcomes using Cox regression. ECV ranged from 16.6% to 47.8%. Over a median of 1.7 years, 111 patients experienced events after cardiovascular magnetic resonance, 55 had hospitalization for heart failure events, and there were 74 deaths. ECV was more strongly associated with outcomes than "nonischemic" MF observed with late gadolinium enhancement, thus ECV quantified MF in multivariable models. Adjusting for age, sex, renal function, myocardial infarction size, ejection fraction, hospitalization status, and heart failure stage, higher ECV was associated with hospitalization for heart failure (hazard ratio 1.77; 95% CI 1.32 to 2.36 for every 5% increase in ECV), death (hazard ratio 1.87 95% CI 1.45 to 2.40) or both (hazard ratio 1.85, 95% CI 1.50 to 2.27). ECV improved classification of persons at risk and improved model discrimination for outcomes (eg, hospitalization for heart failure: continuous net reclassification improvement 0.33, 95% CI 0.05 to 0.66; P=0.02; 0.16, 95% CI 0.01 to 0.33; P=0.02; integrated discrimination improvement 0.037, 95% CI 0.008 to 0.073; P<0.01). CONCLUSION: MF measured by ECV is associated with hospitalization for heart failure, death, or both. MF may represent a principal phenotype of cardiac vulnerability that improves risk stratification. Because MF can be reversible, cells and enzymes regulating collagen could be potential therapeutic targets.


Subject(s)
Heart Failure/epidemiology , Myocardium/pathology , Adult , Female , Fibrosis , Heart Failure/mortality , Heart Failure/pathology , Heart Failure/physiopathology , Hospitalization/statistics & numerical data , Humans , Male , Middle Aged , Proportional Hazards Models , Risk Factors , Severity of Illness Index , Stroke Volume
4.
J Cardiovasc Comput Tomogr ; 8(3): 205-14, 2014.
Article in English | MEDLINE | ID: mdl-24939069

ABSTRACT

OBJECTIVES: To establish current radiation dose levels with contemporary scanners capable of prospectively triggered or high-pitch spiral scan modes to previous generation scanners among patients evaluated for coronary artery disease, pulmonary embolism, aortic disease, and "triple rule out" in a large population of patients at multiple centers. BACKGROUND: Previous small-scale studies with carefully controlled scan protocols report that CT scanners that facilitate prospectively triggered scanning and provide high-pitch spiral CT scan modes drastically lower radiation doses. However, diagnostic reference levels should be selected by medical bodies on the basis of large surveys of representative sites and reviewed at appropriate time intervals. METHODS: Scan data including dose and image quality parameters were collected retrospectively from 64 slice scanners (control) and prospectively after sites installed 128-slice dual-source scanners with high-pitch capability (study). Protocol selection was purposely not specified to survey "real world" results. Blinded quantitative image analysis was performed on every fifth scan. RESULTS: From April 2011 to March 2012, 2085 patients at 9 sites completed the study: 1051 coronary artery disease (509 control, 542 study), 528 pulmonary embolism (267 control, 261 study), 419 aortic disease (268 control, 151 study), and 87 triple rule out (53 control, 34 study). There was a significant reduction in median dose-length product (DLP) from 669 mGy ∙ cm (interquartile range [IQR]: 419-1026 mGy ∙ cm) in the control group to 260 mGy ∙ cm (IQR: 159-441 mGy ∙ cm) in the study group, a reduction by 61% (P < .0001) and was lower in all categories. No significant differences were noted in image quality. CONCLUSION: Use of advanced scanners facilitating prospectively triggered or high-pitch spiral scan modes results in marked dose reduction across a variety of cardiovascular studies, with no compromise in image quality. These findings may contribute to new target dose recommendations in societal guidelines.


Subject(s)
Radiation Dosage , Signal Processing, Computer-Assisted , Tomography, X-Ray Computed/methods , Female , Humans , Male , Middle Aged , Tomography, X-Ray Computed/instrumentation , Tomography, X-Ray Computed/trends
5.
J Am Coll Cardiol ; 58(14): 1414-22, 2011 Sep 27.
Article in English | MEDLINE | ID: mdl-21939822

ABSTRACT

OBJECTIVES: The purpose of this study was to compare the efficiency, cost, and safety of a diagnostic strategy employing early coronary computed tomographic angiography (CCTA) to a strategy employing rest-stress myocardial perfusion imaging (MPI) in the evaluation of acute low-risk chest pain. BACKGROUND: In the United States, >8 million patients require emergency department evaluation for acute chest pain annually at an estimated diagnostic cost of >$10 billion. METHODS: This multicenter, randomized clinical trial in 16 emergency departments ran between June 2007 and November 2008. Patients were randomly allocated to CCTA (n = 361) or MPI (n = 338) as the index noninvasive test. The primary outcome was time to diagnosis; the secondary outcomes were emergency department costs of care and safety, defined as freedom from major adverse cardiac events in patients with normal index tests, including 6-month follow-up. RESULTS: The CCTA resulted in a 54% reduction in time to diagnosis compared with MPI (median 2.9 h [25th to 75th percentile: 2.1 to 4.0 h] vs. 6.3 h [25th to 75th percentile: 4.2 to 19.0 h], p < 0.0001). Costs of care were 38% lower compared with standard (median $2,137 [25th to 75th percentile: $1,660 to $3,077] vs. $3,458 [25th to 75th percentile: $2,900 to $4,297], p < 0.0001). The diagnostic strategies had no difference in major adverse cardiac events after normal index testing (0.8% in the CCTA arm vs. 0.4% in the MPI arm, p = 0.29). CONCLUSIONS: In emergency department acute, low-risk chest pain patients, the use of CCTA results in more rapid and cost-efficient safe diagnosis than rest-stress MPI. Further studies comparing CCTA to other diagnostic strategies are needed to optimize evaluation of specific patient subsets. (Coronary Computed Tomographic Angiography for Systematic Triage of Acute Chest Pain Patients to Treatment [CT-STAT]; NCT00468325).


Subject(s)
Chest Pain/economics , Coronary Angiography/economics , Coronary Artery Disease/economics , Myocardial Perfusion Imaging/economics , Tomography, X-Ray Computed/economics , Triage/economics , Acute Disease , Adult , Chest Pain/diagnostic imaging , Coronary Angiography/methods , Coronary Artery Disease/diagnostic imaging , Cost-Benefit Analysis , Female , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Perfusion Imaging/methods , Tomography, X-Ray Computed/methods , Treatment Outcome , Triage/methods
6.
J Cardiovasc Comput Tomogr ; 5(2): 75-83, 2011.
Article in English | MEDLINE | ID: mdl-21398199

ABSTRACT

Coronary artery calcium (CAC) scanning is an important tool for risk stratification in intermediate-risk, asymptomatic subjects without previous coronary disease. However, the clinical benefit of improved risk prediction needs to be balanced against the risk of the use of ionizing radiation. Although there is increasing emphasis on the need to obtain CAC scans at low-radiation exposure to the patient, very few practical documents exist to aid laboratories and health care professionals on how to obtain such low-radiation scans. The Tomographic Imaging Council of the Society for Atherosclerosis Imaging and Prevention, in collaboration with the Prevention Council and the Society of Cardiovascular Computed Tomography, created a task force and writing group to generate a practical document to address parameters that can be influenced by careful attention to image acquisition. Patient selection for CAC scanning should be based on national guidelines. It is recommended that laboratories performing CAC examinations monitor radiation exposure (dose-length-product [DLP]) and effective radiation dose (E) in all patients. DLP should be <200 mGy × cm; E should average 1.0-1.5 mSv and should be <3.0 mSv. On most scanner platforms, CAC imaging should be performed in an axial mode with prospective electrocardiographic triggering, using tube voltage of 120 kVp. Tube current should be carefully selected on the basis of patient size, potentially using chest lateral width measured on the topogram. Scan length should be limited for the coverage of the heart only. When patients and imaging parameters are selected appropriately, CAC scanning can be performed with low levels of radiation exposure.


Subject(s)
Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Radiation Protection/standards , Radiometry/methods , Tomography, X-Ray Computed , Electrocardiography , Humans , Patient Selection , Radiation Dosage , Risk Assessment , Risk Reduction Behavior
8.
JACC Cardiovasc Imaging ; 3(1): 52-60, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20129531

ABSTRACT

OBJECTIVES: The purpose of the study was to understand determinants of infarct size in a primary percutaneous intervention (PCI) population treated with pexelizumab compared with placebo. BACKGROUND: In the multicenter APEX-AMI (Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction) trial, pexelizumab did not reduce 90-day mortality. Cardiac magnetic resonance (CMR) with delayed enhancement was used in a substudy evaluating infarct size and left ventricular ejection fraction (LVEF). METHODS: Consecutive patients undergoing primary PCI for first myocardial infarction (MI) as part of the APEX-AMI trial were enrolled in this substudy at 5 centers. The CMR was completed on days 3 to 5 (n=99) and day 90 (n=83) following PCI. Central core lab-masked analyses for quantified LVEF, volumes, and infarct size by planimetry were performed. RESULTS: Patients were 60+/-12 years of age, male (n=83 [84%]), had similar time from symptom onset to presentation (median 2.6 h vs. 2.5 h; p=1.0), and similar baseline ST-segment deviation (13.5 mm vs. 14 mm; p=0.59) in both groups. Pexelizumab-treated patients had smaller infarct size (day 3 LV 10.5% vs. 16.2%, p=0.022; day 90 LV 5.9% vs. 12.4%, p=0.015) and higher LVEF (day 3 50.3% vs. 46.2%, p=0.073; day 90 53.9% vs. 49.3%, p=0.036) compared with placebo-treated patients. The median peak creatine kinase in the pexelizumab group was also significantly less than placebo (922 mg/dl vs. 1,973 mg/dl; p=0.03). Notably, the pexelizumab group had lower Thrombolysis In Myocardial Infarction (TIMI) flow grade pre-PCI (46.9% vs. 75.0%; p=0.018), a difference not seen in the overall APEX-AMI study. A multivariate model including baseline features and pexelizumab treatment found anterior MI location and pre-PCI TIMI flow to be significant independent predictors infarct size (p=0.001), whereas pexelizumab was not (p=0.29). No death, heart failure, or shock was noted in either substudy group at 90 days. CONCLUSIONS: In a CMR substudy of pexelizumab in MI, baseline TIMI flow grade and anterior location were the only predictors of infarct size, with a reduction of pre-PCI TIMI flow grade 0 by 28%, leading to a 35% reduction in infarct size. (The APEX-AMI Trial; NCT00091637).


Subject(s)
Angioplasty, Balloon, Coronary , Antibodies, Monoclonal/therapeutic use , Cardiovascular Agents/therapeutic use , Magnetic Resonance Imaging, Cine , Myocardial Infarction/therapy , Myocardium/pathology , Single-Chain Antibodies/therapeutic use , Aged , Angioplasty, Balloon, Coronary/adverse effects , Angioplasty, Balloon, Coronary/mortality , Antibodies, Monoclonal, Humanized , Australia , Chi-Square Distribution , Coronary Circulation/drug effects , Europe , Female , Humans , Linear Models , Male , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/pathology , Myocardial Infarction/physiopathology , North America , Predictive Value of Tests , Risk Assessment , Risk Factors , Stroke Volume/drug effects , Time Factors , Treatment Outcome , Ventricular Function, Left/drug effects
9.
Circ Heart Fail ; 3(1): 51-8, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19850699

ABSTRACT

BACKGROUND: Myocardial late gadolinium enhancement (LGE) on contrast-enhanced magnetic resonance imaging (CE-MRI) of patients with hypertrophic cardiomyopathy (HCM) has been suggested to represent intramyocardial fibrosis and, as such, an adverse prognostic risk factor. We evaluated the characteristics of LGE on CE-MRI and explored whether LGE among patients with HCM was associated with genetic testing, severe symptoms, ventricular arrhythmias, or sudden cardiac death (SCD). METHODS AND RESULTS: Four hundred twenty-four patients with HCM (age=55+/-16 years [range 2 to 90], 41% females), without a history of septal ablation/myectomy, underwent CE-MRI (GE 1.5 Tesla). We evaluated the relation between LGE and HCM genes status, severity of symptoms, and the degree of ventricular ectopy on Holter ECG. Subsequent SCD and appropriate implanted cardioverter defibrillator (ICD) therapies were recorded during a mean follow-up of 43+/-14 months (range 16 to 94). Two hundred thirty-nine patients (56%) had LGE on CE-MRI, ranging from 0.4% to 65% of the left ventricle. Gene-positive patients were more likely to have LGE (P<0.001). The frequencies of New York Heart Association class >or=3 dyspnea and angina class >or=3 were similar in patients with and without LGE (125 of 239 [52%] versus 94 of 185 [51%] and 24 of 239 [10%] versus 18 of 185 [10%], respectively, P=NS). LGE-positive patients were more likely to have episodes of nonsustained ventricular tachycardia (34 of 126 [27%] versus 8 of 94 [8.5%], P<0.001), had more episodes of nonsustained ventricular tachycardia per patient (4.5+/-12 versus 1.1+/-0.3, P=0.04), and had higher frequency of ventricular extrasystoles/24 hours (700+/-2080 versus 103+/-460, P=0.003). During follow-up, SCD occurred in 4 patients, and additional 4 patients received appropriate ICD discharges. All 8 patients were LGE positive (event rate of 0.94%/y, P=0.01 versus LGE negative). Two additional heart failure-related deaths were recorded among LGE-positive patients. Univariate associates of SCD or appropriate ICD discharge were positive LGE (P=0.002) and presence of nonsustained ventricular tachycardia (P=0.04). The association of LGE with events remained significant after controlling for other risk factors. CONCLUSIONS: In patients with HCM, presence of LGE on CE-MRI was common and more prevalent among gene-positive patients. LGE was not associated with severe symptoms. However, LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent SCD and/or ICD discharge after controlling for other variables. If replicated, LGE may be considered an important risk factor for sudden death in patients with HCM.


Subject(s)
Cardiomyopathy, Hypertrophic/diagnosis , Contrast Media , Death, Sudden, Cardiac/etiology , Gadolinium , Adolescent , Adult , Aged , Aged, 80 and over , Cardiomyopathy, Hypertrophic/complications , Child , Child, Preschool , Female , Humans , Image Enhancement/instrumentation , Image Enhancement/methods , Magnetic Resonance Imaging , Male , Risk Factors
10.
J Am Coll Cardiol ; 49(3): 350-7, 2007 Jan 23.
Article in English | MEDLINE | ID: mdl-17239717

ABSTRACT

OBJECTIVES: This study sought to describe the acute morphologic differences that result from septal myectomy and alcohol septal ablation using cardiac magnetic resonance (CMR) imaging. BACKGROUND: Surgical septal myectomy and alcohol septal ablation relieve left ventricular outflow tract obstruction in severely symptomatic patients with hypertrophic cardiomyopathy (HCM). METHODS: Cine and contrast-enhanced CMR images were obtained in HCM patients before and after septal myectomy (n = 24) and alcohol septal ablation (n = 24). Location of septal reduction, extent of myocardial necrosis, and conduction system abnormalities with each technique were compared. RESULTS: With septal myectomy, there was a discrete area of resected tissue consistently localized to anterior septum. In contrast, alcohol septal ablation resulted in a more variable effect. In most patients, alcohol septal ablation caused a transmural region of tissue necrosis, located more inferiorly in the basal septum than myectomy and usually extending into the right ventricular side of the septum at the midventricular level. However, there were 6 patients after alcohol septal ablation in whom there was sparing of the basal septum with residual gradients at follow-up. After the procedure, left bundle branch block developed in 46% of septal myectomy patients, and right bundle branch block was evident in 58% of alcohol septal ablation patients. CONCLUSIONS: Septal myectomy and alcohol septal ablation for severely symptomatic, drug-refractory patients with obstructive HCM have different morphologic effects and location sites on left ventricular septal myocardium. Septal myectomy provides consistent resection of the obstructing portion of the anterior basal septum, whereas the effect of ethanol septal ablation is more variable. These findings may have important implications for patient selection and management as well as long-term outcome.


Subject(s)
Cardiac Surgical Procedures/methods , Cardiomyopathy, Hypertrophic/diagnosis , Cardiomyopathy, Hypertrophic/surgery , Catheter Ablation/methods , Ethanol/therapeutic use , Adult , Aged , Cardiomyopathy, Hypertrophic/mortality , Chi-Square Distribution , Female , Follow-Up Studies , Heart Septum/surgery , Humans , Magnetic Resonance Imaging, Cine , Male , Middle Aged , Probability , Prospective Studies , Risk Assessment , Severity of Illness Index , Survival Rate , Treatment Outcome , Ventricular Function, Left/physiology
11.
Catheter Cardiovasc Interv ; 66(3): 375-89, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16216025

ABSTRACT

Alcohol septal ablation for the treatment of hypertrophic cardiomyopathy has been the subject of great interest, and the number of procedures performed is increasing despite an absence of randomized trial data. Although straightforward in concept, alcohol septal ablation may be considerably more difficult in actual practice. To optimize the results and prevent complications, the anatomy of the septal arcade architecture must be understood and the anatomic relationship between the septal artery and the specific portion of the septum to be ablated must be carefully delineated. For the latter, during the procedure, an echocardiographic contrast medium injection into the septal artery of interest is essential. Selection of the volume and amount of alcohol to be injected varies depending on the size and distribution of the septal artery. Specific complications such as conduction defects, hemodynamic compromise, ventricular arrhythmias, and inadequate gradient reduction can be minimized by specific technical approaches. After ablation, protocols are needed for periprocedural guidelines because some complications may occur late during the next several days. For optimal results, patients need to be selected after catheter assessment and combined echocardiography and angiography, and ablation techniques need to be scientific and rigorous.


Subject(s)
Cardiomyopathy, Hypertrophic/drug therapy , Ethanol/administration & dosage , Heart Septum , Humans , Injections, Intralesional , Treatment Outcome
12.
Circulation ; 111(14): 1771-6, 2005 Apr 12.
Article in English | MEDLINE | ID: mdl-15809375

ABSTRACT

BACKGROUND: In a recent study, we reported that the Duke treadmill score was unable to effectively stratify elderly patients according to risk. The purpose of this study was to evaluate the prognostic value of exercise single-photon emission computed tomography (SPECT) in this same population and to examine results by gender. METHODS AND RESULTS: A cohort of 247 elderly (age > or =75 years) patients (108 women, 139 men, age 77+/-3 years) who underwent exercise thallium-201 SPECT were followed up for a median duration of 6.4 years. SPECT variables were significantly associated with cardiac death: summed stress score (SSS) chi2=19.5, P<0.001; summed difference score chi2=12.3, P<0.001; increased lung uptake chi2=9.6, P=0.002; and left ventricular enlargement chi2=8.3, P=0.004. The Duke score was not significantly associated with cardiac death (chi2<1, P=NS). The SSS classified most patients as low risk (49%) or high risk (35%); the Duke score classified the majority (68%) as intermediate risk. Annual cardiac mortality rates for patients categorized by SSS as low risk and high risk were 0.8% and 5.8%, respectively. Cardiac survival rates according to SSS risk categories were significantly different for both women (P=0.012) and men (P=0.003). CONCLUSIONS: SPECT classified most elderly patients into clinically useful low- and high-risk categories and accurately predicted outcomes in both genders. If these results can be validated in future studies, exercise SPECT rather than standard treadmill testing may emerge as the initial noninvasive testing strategy in elderly patients who are able to exercise.


Subject(s)
Coronary Artery Disease/diagnosis , Coronary Artery Disease/mortality , Exercise Test , Predictive Value of Tests , Tomography, Emission-Computed, Single-Photon , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Male , Prognosis , Retrospective Studies , Risk Assessment , Severity of Illness Index , Sex Factors , Survival Analysis , Thallium Radioisotopes
13.
J Am Coll Cardiol ; 44(12): 2329-32, 2004 Dec 21.
Article in English | MEDLINE | ID: mdl-15607394

ABSTRACT

OBJECTIVES: This study was designed to evaluate the effect of septal reduction therapies on the conduction system for patients with hypertrophic cardiomyopathy (HCM). BACKGROUND: Heart block is a potential complication of both catheter-based and surgical procedures to relieve left ventricular outflow tract obstruction in HCM, but it is important to understand the different effects of these treatments on the conduction system. METHODS: The electrocardiograms and postoperative course of patients who underwent percutaneous alcohol septal ablation or surgical myectomy at Mayo Clinic between 1999 and 2003 were reviewed. RESULTS: For the 58 patients who underwent alcohol septal ablation, 21 (36%) developed right bundle branch block. Six patients (12%) developed complete heart block requiring permanent pacing, three of whom had left bundle branch block before the procedure. Among the 117 patients who underwent surgical septal myectomy, 47 (40%) developed left bundle branch block. Four patients (3%) developed heart block requiring permanent pacing after the procedure, three of whom had right bundle branch block preoperatively. CONCLUSIONS: Percutaneous septal ablation selectively produces transmural infarction of the basal mid-septum and adjacent right bundle tissue, whereas surgical myectomy affects the endocardial portion of the basal anterior septum and adjacent left bundle tissue. These observations may help identify patients at risk for complete heart block after septal reduction procedures for HCM.


Subject(s)
Atrioventricular Node/physiopathology , Cardiac Catheterization , Cardiac Surgical Procedures , Cardiomyopathy, Hypertrophic/drug therapy , Cardiomyopathy, Hypertrophic/surgery , Ethanol/administration & dosage , Heart Block/etiology , Heart Septum/drug effects , Heart Septum/surgery , Bundle-Branch Block/chemically induced , Bundle-Branch Block/epidemiology , Bundle-Branch Block/etiology , Cardiac Pacing, Artificial , Cardiac Surgical Procedures/adverse effects , Cardiomyopathy, Hypertrophic/physiopathology , Ethanol/adverse effects , Ethanol/therapeutic use , Heart Block/chemically induced , Heart Block/epidemiology , Heart Block/therapy , Humans , Incidence , Postoperative Period
14.
J Am Coll Cardiol ; 44(8): 1533-42, 2004 Oct 19.
Article in English | MEDLINE | ID: mdl-15489082

ABSTRACT

We sought to summarize the published evidence regarding the measurement of infarct size by serum markers, technetium-99m sestamibi single-photon emission computed tomography (SPECT) myocardial perfusion imaging, and magnetic resonance imaging. The measurement of infarct size is an attractive surrogate end point for the early assessment of new therapies for acute myocardial infarction. For each of these three approaches, we reviewed reports published in English providing the clinical validation for the measurement of infarct size and the relevant clinical trial experience. The measurement of infarct size by serum markers has multiple theoretical and practical limitations. The measurement of troponin is promising, but the available data validating this marker are limited. Sestamibi SPECT imaging has five separate lines of published evidence supporting its validity and has received extensive study in multicenter trials. Magnetic resonance imaging has great promise but has less clinical validation and no multicenter trial experience. Therefore, SPECT sestamibi imaging is currently the best available technique for the quantitation of infarct size to assess the incremental treatment benefit of new therapies in multicenter trials of acute myocardial infarction.


Subject(s)
Biomarkers/blood , Magnetic Resonance Imaging , Myocardial Infarction/diagnosis , Tomography, Emission-Computed, Single-Photon , Humans , Myocardial Infarction/pathology , Myocardial Infarction/therapy , Myocardial Reperfusion Injury/diagnosis , Myocardial Reperfusion Injury/pathology , Myocardial Reperfusion Injury/therapy , Myocardium/pathology , Prognosis , Sensitivity and Specificity , Technetium Tc 99m Sestamibi
SELECTION OF CITATIONS
SEARCH DETAIL
...